• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随机森林和 Cox 模型预测癌症患者生存的最优 microRNA 测序深度。

Optimal microRNA Sequencing Depth to Predict Cancer Patient Survival with Random Forest and Cox Models.

机构信息

Univ. Grenoble Alpes, CEA, Inserm, IRIG, BioSanté U1292, BCI, 38000 Grenoble, France.

Univ. Grenoble Alpes, CNRS, Grenoble INP, GIPSA-Lab, Institute of Engineering University Grenoble Alpes, 38000 Grenoble, France.

出版信息

Genes (Basel). 2022 Dec 2;13(12):2275. doi: 10.3390/genes13122275.

DOI:10.3390/genes13122275
PMID:36553544
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9777708/
Abstract

(1) Background: tumor profiling enables patient survival prediction. The two essential parameters to be calibrated when designing a study based on tumor profiles from a cohort are the sequencing depth of RNA-seq technology and the number of patients. This calibration is carried out under cost constraints, and a compromise has to be found. In the context of survival data, the goal of this work is to benchmark the impact of the number of patients and of the sequencing depth of miRNA-seq and mRNA-seq on the predictive capabilities for both the Cox model with elastic net penalty and random survival forest. (2) Results: we first show that the Cox model and random survival forest provide comparable prediction capabilities, with significant differences for some cancers. Second, we demonstrate that miRNA and/or mRNA data improve prediction over clinical data alone. mRNA-seq data leads to slightly better prediction than miRNA-seq, with the notable exception of lung adenocarcinoma for which the tumor miRNA profile shows higher predictive power. Third, we demonstrate that the sequencing depth of RNA-seq data can be reduced for most of the investigated cancers without degrading the prediction abilities, allowing the creation of independent validation sets at a lower cost. Finally, we show that the number of patients in the training dataset can be reduced for the Cox model and random survival forest, allowing the use of different models on different patient subgroups.

摘要

(1) 背景:肿瘤分析可用于预测患者的生存率。基于队列肿瘤分析设计研究时,两个需要校准的基本参数是 RNA-seq 技术的测序深度和患者数量。这种校准是在成本限制下进行的,因此必须找到一个折衷方案。在生存数据的背景下,这项工作的目标是比较 Cox 模型和弹性网络惩罚随机生存森林中患者数量和 miRNA-seq 和 mRNA-seq 测序深度对预测能力的影响。(2) 结果:我们首先表明,Cox 模型和随机生存森林具有相当的预测能力,对于某些癌症有显著差异。其次,我们证明了 miRNA 和/或 mRNA 数据可以提高预测能力,优于单独的临床数据。mRNA-seq 数据的预测能力略优于 miRNA-seq,但肺腺癌是一个显著的例外,肿瘤 miRNA 谱显示出更高的预测能力。第三,我们证明,对于大多数研究的癌症,RNA-seq 数据的测序深度可以降低,而不会降低预测能力,从而可以以更低的成本创建独立的验证集。最后,我们表明,Cox 模型和随机生存森林的训练数据集的患者数量可以减少,从而可以在不同的患者亚组上使用不同的模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3cb/9777708/fcb6eb99b88e/genes-13-02275-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3cb/9777708/6380e91b52f4/genes-13-02275-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3cb/9777708/fcb6eb99b88e/genes-13-02275-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3cb/9777708/6380e91b52f4/genes-13-02275-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3cb/9777708/fcb6eb99b88e/genes-13-02275-g002.jpg

相似文献

1
Optimal microRNA Sequencing Depth to Predict Cancer Patient Survival with Random Forest and Cox Models.随机森林和 Cox 模型预测癌症患者生存的最优 microRNA 测序深度。
Genes (Basel). 2022 Dec 2;13(12):2275. doi: 10.3390/genes13122275.
2
Cancer survival classification using integrated data sets and intermediate information.基于整合数据集和中间信息的癌症生存分类。
Artif Intell Med. 2014 Sep;62(1):23-31. doi: 10.1016/j.artmed.2014.06.003. Epub 2014 Jun 21.
3
Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung.联合 RNA 预后标志物在肺腺癌中的鉴定。
Med Sci Monit. 2019 May 27;25:3941-3956. doi: 10.12659/MSM.913727.
4
Prognosis of lasso-like penalized Cox models with tumor profiling improves prediction over clinical data alone and benefits from bi-dimensional pre-screening.具有肿瘤特征分析的套索惩罚 Cox 模型的预后可提高预测准确性,优于仅使用临床数据的预测,并且受益于二维预筛选。
BMC Cancer. 2022 Oct 5;22(1):1045. doi: 10.1186/s12885-022-10117-1.
5
A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.一个与肿瘤微环境相关的 mRNA-ncRNA 特征,用于预测早期肺腺癌的早期复发和化疗敏感性。
J Cancer Res Clin Oncol. 2021 Nov;147(11):3195-3209. doi: 10.1007/s00432-021-03718-z. Epub 2021 Jul 21.
6
A novel 14-gene signature for overall survival in lung adenocarcinoma based on the Bayesian hierarchical Cox proportional hazards model.基于贝叶斯层次 Cox 比例风险模型的肺腺癌总体生存的新型 14 基因标志物。
Sci Rep. 2022 Jan 7;12(1):27. doi: 10.1038/s41598-021-03645-6.
7
Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia.基于 GMI 特征的随机生存森林预后模型的建立与验证及其在急性髓系白血病患者临床预后评估中的应用。
BMC Med Genomics. 2019 Jun 26;12(1):90. doi: 10.1186/s12920-019-0540-5.
8
Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers.五种人类癌症中lncRNA、DNA甲基化、microRNA和mRNA的多种分子数据的预后效用比较
PLoS One. 2015 Nov 25;10(11):e0142433. doi: 10.1371/journal.pone.0142433. eCollection 2015.
9
Multi-omics facilitated variable selection in Cox-regression model for cancer prognosis prediction.多组学技术助力Cox回归模型中的变量选择以进行癌症预后预测。
Methods. 2017 Jul 15;124:100-107. doi: 10.1016/j.ymeth.2017.06.010. Epub 2017 Jun 13.
10
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.微小RNA表达在完全切除的肺腺癌中的预后意义及对厄洛替尼的相关反应
Med Oncol. 2014 Oct;31(10):203. doi: 10.1007/s12032-014-0203-5. Epub 2014 Sep 6.

引用本文的文献

1
DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.DLD 是弥漫性大 B 细胞淋巴瘤患者 COVID-19 感染的潜在治疗靶点。
Apoptosis. 2024 Oct;29(9-10):1696-1708. doi: 10.1007/s10495-024-01959-0. Epub 2024 Apr 6.
2
A Group of Highly Secretory miRNAs Correlates with Lymph Node Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.一组高分泌性 miRNA 与口腔鳞状细胞癌的淋巴结转移和不良预后相关。
Biomolecules. 2024 Feb 15;14(2):224. doi: 10.3390/biom14020224.
3
Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model.

本文引用的文献

1
Prognosis of lasso-like penalized Cox models with tumor profiling improves prediction over clinical data alone and benefits from bi-dimensional pre-screening.具有肿瘤特征分析的套索惩罚 Cox 模型的预后可提高预测准确性,优于仅使用临床数据的预测,并且受益于二维预筛选。
BMC Cancer. 2022 Oct 5;22(1):1045. doi: 10.1186/s12885-022-10117-1.
2
Cancer prognosis with shallow tumor RNA sequencing.浅肿瘤 RNA 测序的癌症预后。
Nat Med. 2020 Feb;26(2):188-192. doi: 10.1038/s41591-019-0729-3. Epub 2020 Feb 10.
3
Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma.
单细胞和空间转录组学的整合分析揭示了胶质母细胞瘤中的细胞异质性景观并建立了多基因风险模型。
Front Oncol. 2023 Jun 15;13:1109037. doi: 10.3389/fonc.2023.1109037. eCollection 2023.
4
Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma.用于预测预后和指导个体化术后化疗的机器学习模型的开发与验证:一项远端胆管癌的真实世界研究
Front Oncol. 2023 Mar 15;13:1106029. doi: 10.3389/fonc.2023.1106029. eCollection 2023.
肿瘤组织切片的体外治疗作为一种预测性临床前方法,用于评估肾癌患者的靶向治疗
Cancers (Basel). 2020 Jan 17;12(1):232. doi: 10.3390/cancers12010232.
4
Combining clinical and molecular data in regression prediction models: insights from a simulation study.将临床和分子数据结合在回归预测模型中:一项模拟研究的见解。
Brief Bioinform. 2020 Dec 1;21(6):1904-1919. doi: 10.1093/bib/bbz136.
5
New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism.胰腺癌新途径:利用 microRNAs 作为预测生物标志物和靶向异常代谢的新方法。
Expert Rev Clin Pharmacol. 2019 Dec;12(12):1081-1090. doi: 10.1080/17512433.2019.1693256. Epub 2019 Nov 24.
6
A plea for taking all available clinical information into account when assessing the predictive value of omics data.呼吁在评估组学数据的预测价值时,考虑所有可用的临床信息。
BMC Med Res Methodol. 2019 Jul 24;19(1):162. doi: 10.1186/s12874-019-0802-0.
7
Challenges in the Integration of Omics and Non-Omics Data.组学与非组学数据整合面临的挑战。
Genes (Basel). 2019 Mar 20;10(3):238. doi: 10.3390/genes10030238.
8
Bioinformatics Methods to Select Prognostic Biomarker Genes from Large Scale Datasets: A Review.生物信息学方法从大规模数据集选择预后生物标志物基因:综述。
Biotechnol J. 2018 Dec;13(12):e1800103. doi: 10.1002/biot.201800103.
9
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.TCGA 泛癌临床数据资源整合,推动高质量生存预后分析。
Cell. 2018 Apr 5;173(2):400-416.e11. doi: 10.1016/j.cell.2018.02.052.
10
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.癌症基因组图谱对肾细胞癌的全面分子特征分析。
Cell Rep. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075.